Cyclophosphamide for ANCA and primary CNS vasculitis – pro
Since 2014, 4 scientific societies have systematically reviewed the existing data and have formulated evidence-based recommendations for the management of AAV antibodies-associate vasculitis. Unfortunately, the type of vasculitis and not been provided for me in this case, except a diagnosis fo primary CNS vasculitis. Since 2014, 4 scientific societies have systematically reviewed the existing data and have formulated evidence-based recommendations for the management of AAV. Primary CNS vasculitis is an uncommon disorder of unknown cause that is restricted to brain and spinal cord. The median age of onset is 50 years. The neurological manifestations are diverse, but generally consist of headache, altered cognition, focal weakness, or stroke. Serological markers of inflammation are usually normal, and it is not antibody associated. It is a rare inflammatory disorder of the blood vessels of the brain and spinal cord occurring in the absence of any evidence of systemic vasculitis. Cyclophosphamide had been reported as treatment for this condition as well.
Geetha D, Jin Q, Scott J, et al. Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Kidney Int Rep. 2018;3(5):1039-1049. Published 2018 May 24.
Godasi R, Pang G, Chauhan S, et al. Primary Central Nervous System Vasculitis. [Updated 2020 Sep 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan
DiCarlo Slvarini et al, Adult primary central nervous system, vasculitis. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60069-5/fulltext